Protein kinases in high grade glioma: Towards therapeutic concoctions

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Brivanib, a Dual FGF/VEGF Inhibitor, Is Active Both First and Second Line against Mouse Pancreatic Neuroendocrine Tumors Developing Adaptive/Evasive Resistance to VEGF Inhibition

  2011cited by this paper
• Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide.

  2011cited by this paper
• Evidence for and against regional differences in neural stem and progenitor cells of the CNS.

  2010cited by this paper
• Cellular functions of FAK kinases: insight into molecular mechanisms and novel functions

  2010cited by this paper
• Gene expression profiling of gliomas: merging genomic and histopathological classification for personalised therapy

  2010cited by this paper
• Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.

  2010cited by this paper
• Therapeutic exploitation of apoptosis and autophagy for glioblastoma.

  2010cited by this paper
• A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry.

  2010cited by this paper
• Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics

  2010cited by this paper
• Exciting New Advances in Neuro‐Oncology: The Avenue to a Cure for Malignant Glioma

  2010cited by this paper
• Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.

  2010cited by this paper
• Targeting focal adhesion kinase signaling in tumor growth and metastasis

  2010cited by this paper
• Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies.

  2010cited by this paper
• Non-stem cell origin for oligodendroglioma.

  2010cited by this paper
• Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours

  2009cited by this paper
• DNA Repair and Resistance of Gliomas to Chemotherapy and Radiotherapy

  2009cited by this paper
• A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM)

  2009cited by this paper
• Targeting multiple kinases in glioblastoma multiforme

  2009cited by this paper
• Focal adhesion kinase: switching between GAPs and GEFs in the regulation of cell motility.

  2009cited by this paper
• Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival.

  2009cited by this paper
• Targeted therapy for malignant glioma patients: Lessons learned and the road ahead

  2009cited by this paper
• Glioma stem cells: a midterm exam.

  2008cited by this paper
• Antiangiogenic therapy in malignant gliomas

  2008cited by this paper
• Comprehensive genomic characterization defines human glioblastoma genes and core pathways

  2008cited by this paper
• Histone Deacetylase Inhibition and Blockade of the Glycolytic Pathway Synergistically Induce Glioblastoma Cell Death

  2008cited by this paper
• Bevacizumab for recurrent malignant gliomas

  2008cited by this paper
• Autocrine factors that sustain glioma invasion and paracrine biology in the brain microenvironment.

  2007cited by this paper
• Combination of sublethal concentrations of epidermal growth factor receptor inhibitor and microtubule stabilizer induces apoptosis of glioblastoma cells

  2007cited by this paper
• AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

  2007cited by this paper
• Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.

  2007cited by this paper
• Inhibiting kinases in malignant gliomas

  2007cited by this paper
• Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma

  2007cited by this paper
• Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: Report from a phase I/II trial

  2006cited by this paper
• Ionizing radiation enhances matrix metalloproteinase-2 secretion and invasion of glioma cells through Src/epidermal growth factor receptor-mediated p38/Akt and phosphatidylinositol 3-kinase/Akt signaling pathways.

  2006cited by this paper
• Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08

  2006cited by this paper
• Biology of vascular endothelial growth factors

  2006cited by this paper
• EGFRvIII as a promising target for antibody-based brain tumor therapy

  2006cited by this paper
• MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy

  2006cited by this paper
• Epidemiology and etiology of gliomas

  2005cited by this paper
• Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas.

  2005cited by this paper
• Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma.

  2005cited by this paper
• Genetic pathways to glioblastomas

  2005cited by this paper
• Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas

  2004cited by this paper
• Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors

  2004cited by this paper
• Pseudopalisades in Glioblastoma Are Hypoxic, Express Extracellular Matrix Proteases, and Are Formed by an Actively Migrating Cell Population

  2004cited by this paper
• IκBαM suppresses angiogenesis and tumorigenesis promoted by a constitutively active mutant EGFR in human glioma cells

  2004cited by this paper
• Targeting the mitogen-activated protein kinase cascade to treat cancer

  2004cited by this paper
• Hypermethylation and transcriptional downregulation of the carboxyl-terminal modulator protein gene in glioblastomas.

  2004cited by this paper
• Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: growth factor and Ras signaling pathways

  2003cited by this paper
• Targeting HIF-1 for cancer therapy

  2003cited by this paper
• Genes and pathways driving glioblastomas in humans and murine disease models

  2003cited by this paper
• Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors.

  2003cited by this paper
• Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2.

  2003cited by this paper
• Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma.

  2003cited by this paper
• Invasion as limitation to anti-angiogenic glioma therapy.

  2003cited by this paper
• Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment.

  2003cited by this paper
• Molecular approaches to brain tumour invasion

  2003cited by this paper
• Regulation of Endothelial Cell Survival and Apoptosis During Angiogenesis

  2002cited by this paper
• Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion.

  2002cited by this paper
• Targeting protein kinase C: new therapeutic opportunities against high-grade malignant gliomas?

  2002cited by this paper
• PDGF and signal transduction in hepatic stellate cells.

  2002cited by this paper
• Malignant glioma: genetics and biology of a grave matter.

  2001cited by this paper
• Migration and invasion in brain neoplasms

  2001cited by this paper
• PTEN-independent induction of caspase-mediated cell death and reduced invasion by the focal adhesion targeting domain (FAT) in human astrocytic brain tumors which highly express focal adhesion kinase (FAK).

  2001cited by this paper
• Carboxyl-Terminal Modulator Protein (CTMP), a Negative Regulator of PKB/Akt and v-Akt at the Plasma Membrane

  2001cited by this paper
• Required role of focal adhesion kinase (FAK) for integrin-stimulated cell migration.

  1999cited by this paper
• Mechanisms of angiogenesis in the brain.

  1999cited by this paper
• Normoxic and hypoxic regulation of vascular endothelial growth factor (VEGF) by astrocytoma cells is mediated by Ras

  1999cited by this paper
• The PTEN lipid phosphatase domain is not required to inhibit invasion of glioma cells.

  1999cited by this paper
• Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN.

  1998cited by this paper
• Inhibition of epidermal growth factor receptor-associated tyrosine kinase blocks glioblastoma invasion of the brain.

  1997cited by this paper
• PTEN gene mutations are seen in high-grade but not in low-grade gliomas.

  1997cited by this paper
• Regulation of Cell Motility by Mitogen-activated Protein Kinase

  1997cited by this paper
• PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer

  1997cited by this paper
• Focal Adhesion Kinase Overexpression Enhances Ras-dependent Integrin Signaling to ERK2/Mitogen-activated Protein Kinase through Interactions with and Activation of c-Src*

  1997cited by this paper
• Glioma invasion in the central nervous system.

  1996cited by this paper
• Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors.

  1995cited by this paper
• Integrin-mediated signal transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase

  1994cited by this paper
• Effects of EGF, BFGF, NGF and PDGF(bb) on cell proliferative, migratory and invasive capacities of human brain‐tumour biopsies In Vitro

  1993cited by this paper
• Prevalence of Glioblastoma Multiforme in Subjects with Prior Therapeutic Radiation

  1992cited by this paper
• Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo

  1992cited by this paper
• Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis

  1992cited by this paper
• ras oncogenes in human cancer: a review.

  1989cited by this paper
• Topographic anatomy and CT correlations in the untreated glioblastoma multiforme.

  1988cited by this paper
• Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification.

  1987cited by this paper
• Tumor angiogenesis: a quantitative method for histologic grading.

  1972cited by this paper
• Tumor angiogenesis: therapeutic implications.

  1971cited by this paper
• The FASEB Journal express article 10.1096/fj.01-0421fje. Published online November 29, 2001.

  year unknowncited by this paper

• Neurofeedback Training Intervention for Enhancing Working Memory Function in Attention Deficit and Hyperactivity Disorder (ADHD) Chinese Students

  2017cites this paper